E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers N > Headlines for Noven Pharmaceuticals Inc. > News item
Published on 6/28/2006 in the Prospect News Biotech Daily.

Jefferies puts Noven at hold

Noven Pharmaceuticals Inc. was rated at hold by Jefferies & Co., Inc. analyst David Windley. Along with Shire Pharmaceuticals, Noven is launching Daytrana, the first patch treatment for ADHD. Shares of the Miami-based pharmaceutical company were down 5 cents, or 0.29%, at $17.00 on volume of 96,683 shares versus the three-month running average of 178,462 shares. (Nasdaq: NOVN)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.